AUTHOR=Park Sehoon , Yang Seung-Hee , Kim Jiyeon , Cho Semin , Yang Jaeseok , Min Sang-Il , Ha Jongwon , Jeong Chang Wook , Bhoo Seong Hee , Kim Yong Chul , Kim Dong Ki , Oh Kook-Hwan , Joo Kwon Wook , Kim Yon Su , Moon Kyung Chul , Song Eun Young , Lee Hajeong 

TITLE=Clinical Significances of Anti-Collagen Type I and Type III Antibodies in Antibody-Mediated Rejection

JOURNAL=Transplant International

VOLUME=Volume 35 - 2022

YEAR=2022

URL=https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2022.10099

DOI=10.3389/ti.2022.10099

ISSN=1432-2277

ABSTRACT=Main problem: It is important to determine the clinical significance of non-human leukocyte antigen (HLA) antibodies and their association with antibody-mediated rejection (ABMR) of kidney allografts.
Methods: We collected post-transplant sera from 68 ABMR patients, 67 T-cell mediated rejection (TCMR) patients, and 83 control subjects without rejection, and determined the levels of 39 non-HLA antibodies. We compared the non-HLA antibody levels among the study groups. We investigated their association with the risk of death-censored graft failure in ABMR cases. 
Results: Among the antibodies evaluated, anti-collagen type I (P = 0.001) and type III (P < 0.001) antibody levels were significantly higher in ABMR cases than in TCMR cases and no-rejection controls. Both anti-collagen type I [per 1 SD, adjusted OR, 11.72 (2.73–76.30)] and type III [per 1 SD, adjusted OR, 6.22 (1.91–31.75)] antibodies were significantly associated with the presence of ABMR. Among ABMR cases, a higher level of anti-collagen type I [per 1 SD, adjusted HR), 1.90 (1.32–2.75)] or type III [adjusted HR, 1.57 (1.15–2.16)] antibody was associated with a higher risk of death-censored graft failure.
Conclusions: Post-transplant anti-collagen I and collagen III antibodies may be novel non-HLA antibodies related to ABMR of kidney allografts.